You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Moodys
Dow
McKesson
Baxter

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Patent: 7,932,267

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,932,267
Title:Use of .alpha.-glucosidase inhibitors to treat alphavirus infections
Abstract: The present invention provides methods for treating a flavivirus infection, including hepatitis C virus (HCV) infection, in an individual suffering from a flavivirus infection. In some embodiments, the methods involve administering to an individual in need thereof an effective amount of an agent that inhibits enzymatic activity of a membrane-bound .alpha.-glucosidase inhibitor. In other embodiments, the methods involve administering to an individual in need thereof effective amounts of an .alpha.-glucosidase inhibitor and at least one additional therapeutic agent.
Inventor(s): Blatt; Lawrence M. (San Francisco, CA), Tan; Hua (Daly City, CA), Seiwert; Scott (Pacifica, CA)
Assignee: Intermune, Inc. (Brisbane, CA)
Application Number:12/617,676
Patent Claims:see list of patent claims

Details for Patent 7,932,267

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Vidara Therapeutics Research Ltd ACTIMMUNE interferon gamma-1b VIAL; SINGLE-USE 103836 001 1999-02-25   Start Trial Intermune, Inc. (Brisbane, CA) 2025-03-08 RX search
Schering PEGINTRON peginterferon alfa-2b VIAL 103949 001 2001-01-19   Start Trial Intermune, Inc. (Brisbane, CA) 2025-03-08 RX search
Schering PEGINTRON peginterferon alfa-2b VIAL 103949 002 2001-01-19   Start Trial Intermune, Inc. (Brisbane, CA) 2025-03-08 RX search
Schering PEGINTRON peginterferon alfa-2b VIAL 103949 003 2001-01-19   Start Trial Intermune, Inc. (Brisbane, CA) 2025-03-08 RX search
Schering PEGINTRON peginterferon alfa-2b VIAL 103949 004 2001-01-19   Start Trial Intermune, Inc. (Brisbane, CA) 2025-03-08 RX search
Schering PEGINTRON peginterferon alfa-2b SYRINGE 103949 005 2001-01-19   Start Trial Intermune, Inc. (Brisbane, CA) 2025-03-08 RX search
Schering PEGINTRON peginterferon alfa-2b SYRINGE 103949 006 2001-01-19   Start Trial Intermune, Inc. (Brisbane, CA) 2025-03-08 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Moodys
Boehringer Ingelheim
McKesson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.